Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Mutation analysis of circulating plasma DNA to determine response to EGFR tyrosine kinase inhibitor therapy of lung adenocarcinoma patients

Long-lasting success in lung cancer therapy using tyrosine kinase inhibitors (TKIs) is rare since the tumors develop resistance due to the occurrence of molecularly altered subclones. The aim of this study was to monitor tumors over time based on the quantity of mutant plasma DNA and to identify ear...

Full description

Bibliographic Details
Main Authors:	Riediger, Anja Lisa, Dietz, Steffen, Schirmer, Uwe, Meister, Michael, Heinzmann-Groth, Ingrid, Schneider, Marc, Muley, Thomas, Thomas, Michael, Sültmann, Holger
Format:	Online
Language:	English
Published:	Nature Publishing Group 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027592/

Similar Items

Low Input Whole-Exome Sequencing to Determine the Representation of the Tumor Exome in Circulating DNA of Non-Small Cell Lung Cancer Patients
by: Dietz, Steffen, et al.
Published: (2016)

Cross-talk between AMPK and EGFR dependent Signaling in Non-Small Cell Lung Cancer
by: Praveen, Paurush, et al.
Published: (2016)

Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?
by: Marcq, Marie, et al.
Published: (2014)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
by: Tseng, Jeng-Sen, et al.
Published: (2014)

Mean platelet volume and lymphocyte-to-monocyte ratio are associated with shorter progression-free survival in EGFR-mutant lung adenocarcinoma treated by EGFR tyrosine kinase inhibitor.
by: Kousuke Watanabe, et al.

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
by: Miyoshi, Seigo, et al.
Published: (2015)

The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
by: Wu, Shang-Gin, et al.
Published: (2016)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
by: Wu, Shang-Gin, et al.
Published: (2016)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Huang, Lihua, et al.
Published: (2015)

Circulating MicroRNAs in Relation to EGFR Status and Survival of Lung Adenocarcinoma in Female Non-Smokers
by: Zhang, Huan, et al.
Published: (2013)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
by: Sousa, Vitor, et al.
Published: (2010)

EGFR unusual mutation status in lung adenocarcinomas
by: Alarcão, Ana, et al.
Published: (2010)

EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
by: Taus, Álvaro, et al.
Published: (2012)

DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma
by: Berger, Alice H., et al.
Published: (2013)

The Association of EGFR Mutations with Stage at Diagnosis in Lung Adenocarcinomas
by: Cho, Jaeyoung, et al.
Published: (2016)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
by: Hung, Ming-Szu, et al.
Published: (2016)

BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations
by: Costa, Daniel B, et al.
Published: (2007)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
by: Tabara, Keisuke, et al.
Published: (2012)

Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib
by: He, Peng, et al.
Published: (2013)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
by: Choi, Yun Jung, et al.
Published: (2013)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
by: Park, Ha Young, et al.
Published: (2016)

Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells
by: Vouri, M, et al.
Published: (2016)

Patients harboring EGFR mutation after primary resistance to crizotinib and response to EGFR-tyrosine kinase inhibitor
by: Wang, Wenxian, et al.
Published: (2016)

The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling
by: Asbagh, Layka Abbasi, et al.
Published: (2014)

Cathepsin S attenuates endosomal EGFR signalling: A mechanical rationale for the combination of cathepsin S and EGFR tyrosine kinase inhibitors
by: Huang, Chien-Chang, et al.
Published: (2016)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang, Jun, et al.
Published: (2016)

In Vitro Activation and Inhibition of Recombinant EGFR Tyrosine Kinase Expressed in Escherichia coli
by: Elloumi-Mseddi, Jihene, et al.
Published: (2013)

Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
by: Park, Jin H., et al.
Published: (2012)

Circulating Tumor Cells in the Adenocarcinoma of the Esophagus
by: Gallerani, Giulia, et al.
Published: (2016)

EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitors
by: Chenguang Li, et al.
Published: (2018-08-01)

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
by: Chen, Yongshun, et al.
Published: (2016)

MLH1 V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients with EGFR L858R-positive lung adenocarcinoma
by: Chiu, Chao-Hua, et al.
Published: (2015)

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study
by: Lee, Ji Hyun, et al.
Published: (2016)

Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking
by: Sugio, K, et al.
Published: (2006)

Can EGFR-Tyrosine Kinase Inhibitors (TKI) Alone Without Talc Pleurodesis Prevent Recurrence of Malignant Pleural Effusion (MPE) in Lung Adenocarcinoma
by: Verma, Akash, et al.
Published: (2016)

A case of Trousseau syndrome caused by pulmonary adenocarcinoma that was controlled for one year and 10 months with thrombosis treatment using an EGFR tyrosine kinase inhibitor and chemotherapy
by: Masubuchi, Hiroaki, et al.
Published: (2015)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
by: Yang, Hua, et al.
Published: (2016)

The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma
by: Ruess, Dietrich A., et al.
Published: (2015)

Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas
by: Gong, Yixuan, et al.
Published: (2007)

EGFR and KRAS mutations in lung carcinomas in the Dutch population: increased EGFR mutation frequency in malignant pleural effusion of lung adenocarcinoma
by: Smits, Alexander J. J., et al.
Published: (2012)